Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) Receives $20.75 Consensus Target Price from Analysts

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) has earned an average rating of “Hold” from the fourteen brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $18.7222.

AVDL has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Avadel Pharmaceuticals in a research note on Friday, August 8th. Craig Hallum lowered shares of Avadel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. HC Wainwright lowered shares of Avadel Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $20.00 price target on the stock. in a report on Thursday. Wall Street Zen downgraded shares of Avadel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Wells Fargo & Company raised shares of Avadel Pharmaceuticals to a “hold” rating in a report on Wednesday, September 3rd.

Avadel Pharmaceuticals Price Performance

Shares of Avadel Pharmaceuticals stock opened at $18.56 on Thursday. Avadel Pharmaceuticals has a 1-year low of $6.38 and a 1-year high of $18.65. The stock has a market cap of $1.80 billion, a P/E ratio of -618.67 and a beta of 1.46. The stock’s 50 day simple moving average is $15.31 and its 200-day simple moving average is $11.61.

Avadel Pharmaceuticals (NASDAQ:AVDL) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.08. The business had revenue of $68.13 million for the quarter, compared to analyst estimates of $60.28 million. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%.The company’s revenue was up 64.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.14) earnings per share. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts expect that Avadel Pharmaceuticals will post -0.51 EPS for the current fiscal year.

Institutional Trading of Avadel Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its holdings in shares of Avadel Pharmaceuticals by 164.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $29,000 after purchasing an additional 2,055 shares during the last quarter. Raymond James Financial Inc. bought a new position in Avadel Pharmaceuticals in the 2nd quarter valued at approximately $65,000. Tower Research Capital LLC TRC raised its holdings in Avadel Pharmaceuticals by 217.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company’s stock worth $78,000 after purchasing an additional 6,025 shares during the last quarter. Thoroughbred Financial Services LLC bought a new stake in shares of Avadel Pharmaceuticals in the 1st quarter valued at $82,000. Finally, Exencial Wealth Advisors LLC acquired a new stake in Avadel Pharmaceuticals in the 1st quarter valued at $82,000. 69.19% of the stock is owned by institutional investors.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.